1. Home
  2. CHRS vs TCX Comparison

CHRS vs TCX Comparison

Compare CHRS & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • TCX
  • Stock Information
  • Founded
  • CHRS 2010
  • TCX 1992
  • Country
  • CHRS United States
  • TCX Canada
  • Employees
  • CHRS 235
  • TCX N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • TCX EDP Services
  • Sector
  • CHRS Health Care
  • TCX Technology
  • Exchange
  • CHRS Nasdaq
  • TCX Nasdaq
  • Market Cap
  • CHRS 134.4M
  • TCX 179.2M
  • IPO Year
  • CHRS 2014
  • TCX 1996
  • Fundamental
  • Price
  • CHRS $1.16
  • TCX $15.53
  • Analyst Decision
  • CHRS Strong Buy
  • TCX
  • Analyst Count
  • CHRS 4
  • TCX 0
  • Target Price
  • CHRS $5.38
  • TCX N/A
  • AVG Volume (30 Days)
  • CHRS 2.4M
  • TCX 23.4K
  • Earning Date
  • CHRS 03-12-2025
  • TCX 02-13-2025
  • Dividend Yield
  • CHRS N/A
  • TCX N/A
  • EPS Growth
  • CHRS N/A
  • TCX N/A
  • EPS
  • CHRS N/A
  • TCX N/A
  • Revenue
  • CHRS $304,340,000.00
  • TCX $356,135,000.00
  • Revenue This Year
  • CHRS $2.47
  • TCX $8.16
  • Revenue Next Year
  • CHRS N/A
  • TCX N/A
  • P/E Ratio
  • CHRS N/A
  • TCX N/A
  • Revenue Growth
  • CHRS 44.19
  • TCX 7.50
  • 52 Week Low
  • CHRS $0.66
  • TCX $14.50
  • 52 Week High
  • CHRS $2.87
  • TCX $26.48
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 38.01
  • TCX 41.13
  • Support Level
  • CHRS $1.03
  • TCX $14.50
  • Resistance Level
  • CHRS $1.39
  • TCX $16.58
  • Average True Range (ATR)
  • CHRS 0.14
  • TCX 0.57
  • MACD
  • CHRS -0.03
  • TCX -0.09
  • Stochastic Oscillator
  • CHRS 14.04
  • TCX 39.31

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About TCX Tucows Inc.

Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains.

Share on Social Networks: